[
    {
        "title": "Hindustan Construction Company Share Price Today Updates: Hindustan Construction Company Sees 4.83% Incr... - Economic Times",
        "description": "Hindustan Construction Company Share Price Today Updates: Hindustan Construction Company Sees 4.83% Incr...  Economic Times",
        "published date": "Wed, 30 Aug 2023 07:00:00 GMT",
        "url": "https://consent.google.com/m?continue=https://news.google.com/rss/articles/CBMiowFodHRwczovL2Vjb25vbWljdGltZXMuaW5kaWF0aW1lcy5jb20vbWFya2V0cy9zdG9ja3Mvc3RvY2stbGl2ZWJsb2cvaGluZHVzdGFuLWNvbnN0cnVjdGlvbi1jb21wYW55LXNoYXJlLXByaWNlLXRvZGF5LWxpdmUtdXBkYXRlcy0zMC1hdWctMjAyMy9saXZlYmxvZy8xMDMxOTA3NjkuY21z0gGnAWh0dHBzOi8vZWNvbm9taWN0aW1lcy5pbmRpYXRpbWVzLmNvbS9tYXJrZXRzL3N0b2Nrcy9zdG9jay1saXZlYmxvZy9oaW5kdXN0YW4tY29uc3RydWN0aW9uLWNvbXBhbnktc2hhcmUtcHJpY2UtdG9kYXktbGl2ZS11cGRhdGVzLTMwLWF1Zy0yMDIzL2FtcF9saXZlYmxvZy8xMDMxOTA3NjkuY21z?oc%3D5&gl=IT&m=0&pc=n&cm=2&hl=en-US&src=1"
    },
    {
        "title": "PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib - Yahoo Finance",
        "description": "PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib  Yahoo Finance",
        "published date": "Wed, 30 Aug 2023 07:00:00 GMT",
        "url": "https://consent.google.com/m?continue=https://news.google.com/rss/articles/CBMiTmh0dHBzOi8vZmluYW5jZS55YWhvby5jb20vbmV3cy9wbG9zLW9uZS1wdWJsaXNoZXMtZGF0YS1hbGxhcml0eS0yMDA1MDA1MDQuaHRtbNIBVmh0dHBzOi8vZmluYW5jZS55YWhvby5jb20vYW1waHRtbC9uZXdzL3Bsb3Mtb25lLXB1Ymxpc2hlcy1kYXRhLWFsbGFyaXR5LTIwMDUwMDUwNC5odG1s?oc%3D5&gl=IT&m=0&pc=n&cm=2&hl=en-US&src=1"
    },
    {
        "title": "Exelixis: Predominantly Single Molecule Cancer Franchise ... - Seeking Alpha",
        "description": "Exelixis: Predominantly Single Molecule Cancer Franchise ...  Seeking Alpha",
        "published date": "Wed, 30 Aug 2023 07:00:00 GMT",
        "url": "https://consent.google.com/m?continue=https://news.google.com/rss/articles/CBMiZmh0dHBzOi8vc2Vla2luZ2FscGhhLmNvbS9hcnRpY2xlLzQ2MzE5MDUtZXhlbGl4aXMtc3RvY2stcHJlZG9taW5hbnRseS1zaW5nbGUtbW9sZWN1bGUtY2FuY2VyLWZyYW5jaGlzZdIBAA?oc%3D5&gl=IT&m=0&pc=n&cm=2&hl=en-US&src=1"
    },
    {
        "title": "Novartis Discontinues Development of NIS793 in Pancreatic Cancer - OncLive",
        "description": "Novartis Discontinues Development of NIS793 in Pancreatic Cancer  OncLive",
        "published date": "Wed, 30 Aug 2023 07:00:00 GMT",
        "url": "https://consent.google.com/m?continue=https://news.google.com/rss/articles/CBMiXWh0dHBzOi8vd3d3Lm9uY2xpdmUuY29tL3ZpZXcvbm92YXJ0aXMtZGlzY29udGludWVzLWRldmVsb3BtZW50LW9mLW5pczc5My1pbi1wYW5jcmVhdGljLWNhbmNlctIBAA?oc%3D5&gl=IT&m=0&pc=n&cm=2&hl=en-US&src=1"
    },
    {
        "title": "Social Work England consults on best interests assessor training ... - Communitycare.co.uk",
        "description": "Social Work England consults on best interests assessor training ...  Communitycare.co.uk",
        "published date": "Wed, 30 Aug 2023 07:00:00 GMT",
        "url": "https://consent.google.com/m?continue=https://news.google.com/rss/articles/CBMidmh0dHBzOi8vd3d3LmNvbW11bml0eWNhcmUuY28udWsvMjAyMy8wOC8zMC9zb2NpYWwtd29yay1lbmdsYW5kLWNvbnN1bHRzLW9uLWJlc3QtaW50ZXJlc3RzLWFzc2Vzc29yLXRyYWluaW5nLXN0YW5kYXJkcy_SAQA?oc%3D5&gl=IT&m=0&pc=n&cm=2&hl=en-US&src=1"
    }
]